Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Consensus Rating of “Buy” by Analysts

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has been assigned an average rating of “Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $12.6250.

A number of equities research analysts have recently issued reports on CATX shares. Royal Bank Of Canada cut their price objective on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating for the company in a research note on Tuesday, March 17th. BTIG Research reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. UBS Group upped their price objective on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. B. Riley Financial upped their price objective on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Finally, Piper Sandler assumed coverage on shares of Perspective Therapeutics in a report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price target for the company.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Patient Square Capital LP purchased a new stake in Perspective Therapeutics during the 3rd quarter valued at about $1,198,000. Siligmueller & Norvid Wealth Advisors LLC purchased a new stake in Perspective Therapeutics during the 3rd quarter valued at about $565,000. UBS Group AG grew its position in Perspective Therapeutics by 44.5% during the 4th quarter. UBS Group AG now owns 926,331 shares of the company’s stock valued at $2,547,000 after purchasing an additional 285,188 shares during the last quarter. R Squared Ltd purchased a new stake in Perspective Therapeutics during the 4th quarter valued at about $44,000. Finally, Taylor & Morgan Wealth Management LLC grew its position in Perspective Therapeutics by 6.6% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company’s stock valued at $267,000 after purchasing an additional 6,000 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Stock Down 1.1%

Shares of Perspective Therapeutics stock opened at $3.56 on Thursday. Perspective Therapeutics has a 52-week low of $1.96 and a 52-week high of $6.16. The company has a fifty day moving average of $4.10 and a 200-day moving average of $3.74.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.16 million. Analysts predict that Perspective Therapeutics will post -1.13 earnings per share for the current fiscal year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.